Ads
related to: platinum sensitive ovarian cancer treatmentsidekickbird.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
The ARIEL3 and ARIEL4 are two randomized, double-blind phase III studies. The ARIEL3 study was designed to evaluate the effect of the investigational agent as a maintenance treatment for the advanced platinum-sensitive ovarian cancer patients compared placebo after their response to at least two prior chemotherapies.
[27] it started in 2013 a phase III for metastatic germline BRCA mutated breast cancer. [28] Veliparib June 2014 in phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC). [29] Pamiparib (BGB-290) For ovarian cancer, 1st patient enrolled May 2018. [30] It is a PARP1 and PARP2 ...
In the European Union, niraparib is indicated: as monotherapy for the maintenance treatment of adults with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy; and as monotherapy for ...
Elahere was approved for adult patients with a type of cancer which affects the ovaries, fallopian tube, or walls of the abdomen, and have received one to three prior lines of treatment, according ...
If ovarian cancer recurs, it is considered partially platinum-sensitive or platinum-resistant, based on the time since the last recurrence treated with platins: partially platinum-sensitive cancers recurred 6–12 months after last treatment, and platinum-resistant cancers have an interval of less than 6 months.
In people with platinum-sensitive relapsed EOC, research has found that Pegylated Liposomal Doxorubicin with Carboplatin is a better treatment than Paclitaxel with Carboplatin. [20] There is also evidence to suggest that Pegylated Liposomal Doxorubicin with Carboplatin is tolerated better by people with platinum-sensitive relapsed EOC. [20]
Nanotechnology has been explored to deliver platinum more efficiently in the case of lipoplatin, which is introduced into the tumor sites thereby reducing the chance of toxicity. [8] Cisplatin was the first to be developed. [9] Cisplatin is particularly effective against testicular cancer; the cure rate was improved from 10% to 85%. [10]
Testicular cancer, ovarian cancer, lung cancer, acute myeloid leukaemia, lymphomas and sarcomas: Myelosuppression, hypersensitivity reactions, Stevens–Johnson syndrome (rare), peripheral neuropathy (uncommon) and secondary malignancies (especially acute myeloid leukaemia). Teniposide: IV: Topoisomerase II inhibitor.
Ads
related to: platinum sensitive ovarian cancer treatmentsidekickbird.com has been visited by 100K+ users in the past month